Mohammad Jad Moussa: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation

Mohammad Jad Moussa, Postdoc Fellow of GU Oncology at MD Anderson Cancer Center, shared a post on X:

“NOW IN PRESS: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy

• GU ASCO GU24: Original multi-institutional series on off-label use of lurbi in SCBC-enriched GU cohorts Omar Alhalabi, Parminder Singh, Alan Bryce.
• ASCO24: Phase II LASER study announcement (lurbi +/- avelumab) Saad Atiq, Andrea Apolo
• Now: Our structured report Current Oncology with a hypothesis-testing paradigm, awaiting objective response.”

Read further.
Source: Mohammad Jad Moussa/X